期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 182, 期 1-2, 页码 204-211出版社
ELSEVIER
DOI: 10.1016/j.jneuroim.2006.09.012
关键词
ex vivo; in vitro; interferon beta-1a; regulatory T-cell; relapsing-remitting multiple sclerosis
Interferon beta-1a (IFNa-1a) has demonstrated efficacy in multiple sclerosis (MS), although its mechanism of action remains only partly understood. We evaluated the ex vivo and in vitro effects of IFNa-1a (Rebif((R))) on regulatory T-cell (T-Reg) function in 22 relapsing-remitting MS patients and 16 healthy controls. T-Reg function was significantly enhanced after 3 and 6 months of IFN beta-1a therapy. Furthermore, there was a trend towards increasing proportions of total CD4(+)CD25(+) and CD4(+)CD25(+)GITR(+) T-Reg after 6 months of IFN beta-1a therapy when compared with baseline. In conclusion, IFN beta-1a therapy enhances T-Reg function, and this may be relevant in the inflammatory environment of MS lesions. (c) 2006 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据